Interim results presentation

1. 2013 Financial Year Interim results presentation

2. Disclaimer • This presentation has been prepared by Nuplex Industries Limited. The material that follows contains general background information about Nuplex’s activities as at the date of the presentation 21 February 2013. • The information in this presentation is not an offer or recommendation to purchase or subscribe for securities in Nuplex or to retain any securities currently held. It does not take into account the potential and current individual investment objectives or the financial situation of investors. • Actual results may vary materially either positively or negatively from any forecasts in this presentation. Before making or disposing of any investment in Nuplex securities, investors should consider the appropriateness of that investment in light of their individual investment objectives and financial situation, and seek their own professional advice. • All currencies are in NZD unless stated otherwise.

3. Safety • Making progress towards our goal of zero harm Lost time injury frequency rate per million employee hours worked 0 Total reportable injury frequency rate per million employee hours worked 10.2

4. 1H13 financial overview Sales revenue $828.7m up 11.0% EBITDA1 $57.6m steady NPAT2 after significant items $11.5m down 52.3% NPAT before significant items $24.5mdown 9.6% Earnings per share 5.8 cents down from 12.3 cents Dividend per share 10 cents unchanged Return of funds employed3 9.8%down from 12.1% Working capital to sales ratio 14.8%down from 16.5% 1 Earnings before interest, tax, depreciation and amortisation 2 Net profit after tax attributable to equity holders of the parent company 3 As defined by earnings before interest, tax and unusual items divided by average funds All figures are in NZD unless otherwise stated

5. 1H13 in review • Taking action to improve returns on funds employed • Existing operations steady despite significant weakness in Australia and volatility in Europe in November/ December • Resins segment excluding acquisitions • Volume growth due to Asia and Americas offsetting ANZ and Europe • Unit margins up 3.4%1 • Strengthening Nuplex by reducing costs • Restructuring Australia and New Zealand to adapt to changing markets • Executing NuLEAP I - delivered $6m during 1H13, on track to deliver program target of $30m net benefits by the end of the FY13 • Investing in NuLEAP II - procurement initiative to deliver $5.3m in 2H13, $12m in FY14 • Acquisitions successfully integrated – delivering in line with forecast in FY13 and acquisition criteria • Viverso on track to deliver EBITDA of €12m • Nuplex Masterbatch on track to deliver EBITDA of A$5m 1. Defined as a unit margin as a percentage of sales = sales revenue minus raw material costs divided by tonnage All figures in NZD unless otherwise stated

6. 1H13 key financial outcomes • EBITDA • Supported by Viverso and Masterbatch contributions • Impacted by • ANZ restructure and procurement costs • Ongoing strength of the New Zealand dollar • Geographic diversity supported existing operations • Weakness in Australia and end-of-year slow down in EMEA largely mitigated by growth in Asia and Americas • NPAT impacted by write downs • $13m in significant items including • $5.8m write down of obsolete equipment in ANZ • $5.5m write down of Fibrelogic investment • Interim dividend maintained at 10 cents per share • Strong cash flows reflecting margin management and tight cost control • Declared in context of the outlook for the full year 1 See slide 25 for underlying data, 2. Excluding acquisitions All figures in NZD unless otherwise stated

7. 1H13 earnings drivers • Solid EBITDA despite continued challenging market conditions particularly in Australian coating resins business $57.6m $57.3m (2.1) 3.2 0.5 (3.1)* 1.5* (7.3) (6.1) 8.6 (4.5)* 9.7 NZ$ million 1H12 EBITDA Resinsvolume* Unit margin* Spec-ialties Cost inflation - wages, utilities etc Other fixed costs NuLEAP - benefit increase from 1H12 to 1H13 Restruc-tureand procure-mentcosts at 1H12 FX rates Viverso at 1H12 FX rates Master-batch at 1H12 FX rates FX 1H13 EBITDA *Excluding the impact of NuLEAP initiatives and acquisitions

8. Meeting challenging market conditions in ANZ with action 7sites • Restructuring to improve returns Pre-restructure • Reducing capacity to meet future demand • Closing 1 site in New Zealand, 2 in Australia • Expected restructure costs $9.6m1 • Closures to occur 1st half FY14 • Investing to improve efficiency and further reduce costs • Investing $13m to improve customer responsiveness and efficiency • Benefits to flow from 2H13 • 2H13: $0.5m in cost savings • FY14: $3.7m cost savings, 0.5 cents EPS uplift • FY15: fully realised $5.6m cost savings, 2 cents EPS uplift 4sites Post-restructure 1 Timing of expected restructure costs 1H13 $2.8m, 2H13 $4.0m, FY14 $2.8 All figures in NZD unless otherwise stated

9. Meeting challenging market conditions with action • Improving procurement and delivering significant cost savings NuLEAPI on track to deliver $30m net benefits by end FY13 1H13 $6m realised • 40% procurement, 40% sales, 20% operating costs • Resins segment unit margins up 3.4% NuLEAP II transformative procurement initiative Adopting a center-led approach supported by regional hubs Invested $3.2m in 1H13 Benefits from this initiative to flow from 2H13 • $5.3m in 2H13 • $12m in FY14 Decentralised Center-led Country procurement managers Global category managers Site buyer Regional procurement managers Implementing • Strategic sourcing processes • Category management disciplines All figures in NZD unless otherwise stated

10. Specialties Global resins segment Resins • EBITDA including Viverso $45.2m down 3.6% (up 0.6% constant FX) • Includes $6m in costs to restructure ANZ ($2.8m) and upfront costs of procurement initiative ($3.2m) • EBITDA excluding Viverso, restructure and procurement costs $42.4m down 8.5% (down 6.4% constant FX) • Viverso • Integration complete with successful transition of complex IT systems • 1H13 performance in line with management expectations • On track to deliver €12m in FY13 • Focus now on operational improvement and leveraging product portfolio • Europe, Middle East & Africa (EMEA) • 2.5% volume growth ex Viverso • – Growth in powder resins • – Decorative, Marine & Protective and Auto OEM resins segments weaker • EBITDA ex Viverso €9.2m down 3.2% • – Earlier than usual end-of-year slowdown • – Increased R&D costs, contribution to employee fund • Asia • 10.3% volume growth • – Growth in China (Auto OEM, Vehicle Refinish), Indonesia (Decorative) & Malaysia (Regional exports) • EBITDA US$12.1m up 16.3% • Contribution from sale of Viverso products • Vietnam impacted by slowdown in housing market. New capacity still expected to be filled in 4 years • Americas • 3.7% volume growth • – Growth in higher margin High End Metal coatings • EBITDA US$7.3m up 40.4% • Tight cost control • Contribution from sale of Viverso products • Australia & New Zealand • Volumes down 11.4% • EBITDA A$3.8m down 56.8% after A$1.6m restructure costs • Cyclical low construction activity impacted demand • Importation of finished goods continued to impact manufacturing customers • Margin management and cost control mitigated some of volume impact All figures in NZD unless otherwise stated

11. Specialties ANZ specialties segment Resins • EBITDA $12.4m up 19.2% (up 20.2% constant FX) Agency and distribution Defensive sectors growing Food and nutrition growing due to chocolate Pharmaceutical and healthcare Ongoing weakness in plastics, foam, paints and coatings Nuplex Masterbatch Integration/restructure complete 2 sites closed Improved margins Enhanced customer offering: expanded colour range, black and performance additives Delivering in line with acquisition base case On track to deliver A$5m EBITDA in FY13 All figures in NZD unless otherwise stated

12. 2. Financial results

13. Financial results

14. Reconciliation: EBITDA to cash flow

15. Working capital and capital expenditure Working capital to sales ratio 14.8% Stay in business capex • 1H13: $12.2m, equivalent to 95.4% of depreciation • $2.9m global ERP project • $2.3m new reactors at Botany, Wacol, and East St.Louis • $1.2m Suzhou Technical Centre • FY13: expected to be 120% of depreciation Organic growth capex • 1H13: $6.7m • China new site $4.8m • FY13 forecast approximately $20m • FY14 forecast $25 to $30m Working capital as a percentage of 12-month rolling sales Target range 15-17% All figures in NZD unless otherwise stated

16. Funding and gearing $209m net debt as at 31 December 2012 • Largely unchanged from $220m as at 30 June 2012 Average cost of debt 6.6% Completed US$105m US private placement funding • 7 year term, mature 2019 • Coupon rate 6.125% • Settled 31 July 2012 NZ$52.6m of Capital Notes redeemed September 2012 Net debt to net debt plus equity ratio Target range 20-35% 27.4% Note: All figures are in NZD unless otherwise stated

17. 3. Strategy and outlook

18. We’re strengthening and growing Nuplex Our ambition To be the leading, trusted independent polymer resins manufacturer globally, and leading agency and distribution business in ANZ Our strategy To achieve superior shareholder returns by delivering high quality products to our customers through pursuing operational excellence, innovation and building market leading positions Strengthening through operational excellence Growing through building market leading positions Safety People NuLEAP Emerging markets R&D Strategic acquisitions • Build a culture of ‘zero harm’ • Engage and leverage One Global Team • Introduce global Overlay Teams to leverage products, R&D and procurement across the group • Improve the way we work through rigorous improvement programs • Profitably expand capacity and presence in emerging markets • Grow market share through innovative products • Pursue market development opportunities • Leverage technologies across global platform • Consider acquisitions that • Strengthen leading market & technology positions • Leverage capabilities • Meet disciplined criteria FY2013 Execution • Implementing global common standards relating to processes and policies • Health & Wellbeing program in ANZ • Global Senior Management Conference • Employee survey • Nuplex Leadership Academy: online development program • NuLEAPI • Final phase of execution • NuLEAP II • Planning • Procurement initiative • Restructure of Australia and New Zealand • Preparing for launch of new products at European Coatings Show in March 2013 • Succession planning for R&D personnel • Consolidation of recent acquisitions • Integration • Improving operational performance • Leveraging benefits of product portfolio • China: 3rd site progressing US$35m • Indonesia: cap-acityexpansion US$5.4m • Russia: finalising JV • Thailand: cap-acityexpansion

19. Building leading positions where our markets are developing and growing • China, Changshu • Investing US$35m • Double capacity in China • Delayed 6 months • Commissioning now expected end FY14 Sales by region1 % 100% • Indonesia, Surabaya • Investing US$5.4m • Expanding capacity and adding new technology • Commissioning expected end FY14 100% 100% • Thailand, Bangkok • Joint venture • Investing US$1.5m • Expanding powder capacity 40% • Funded from cash within JV Americas Asia EMEA • Russia, Belgorod • Joint venture negotiations nearing completion • Expect to be operating 4th quarter FY13 • Initial investment of €8m in existing plant & equipment and working capital – Nuplex equity investment €2.5m • Working towards starting construction of new site in 2014 – estimated investment €20 million, Nuplex share 50% ANZ expected (base case2) 1. FY09 sales retranslated at FY12 exchange rates 2. Forecast subject to unforeseen circumstances and economic uncertainty

20. FY13 guidance • 2013 so far • ANZ • New Zealand: in recovery mode • Australia: bouncing along the bottom? • Asia • China: signs of an upturn in China • SE Asia: growing steadily • Europe • While activity is volatile, demand steady • Americas • Steady growth FY13 earnings guidance • EBITDA now expected to be between $135m and $140m • Assumes similar market conditions in 2H13 • Is based on 1H13 average exchange rates • Acquisitions on track to deliver EBITDA targets; Viverso €12m, Nuplex Masterbatch $5m • NuLEAP on track to deliver at least $13m • Procurement initiative to deliver benefits of $5.3m in the second half • ANZ restructure costs of $6.8m Note: All figures are in NZD unless otherwise stated

21. FOR FURTHER DETAILS: • Emery Severin • Chief Executive Officer •  +61 2 8036 0902 •  emery.severin@nuplex.com • Josie Ashton • Investor Relations • +61 2 8036 0906 or  +61 416 205 234 •  josie.ashton@nuplex.com